Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-128 in healthy subjects
NCT05130567Phase 1Active, not recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LP-128 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Lupeng Pharmaceutical. Primary endpoints: Area under the plasma concentration-time curve of LP-128 up to 17 days, Apparent terminal phase half-life of LP-128 up to 17 days and 2 more. Started Nov 2021; status: active, not recruiting.
02
Drugs
LP-128
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05130567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130567.